Your browser doesn't support javascript.
loading
Comparison of non-pharmaceutical treatments for evaporative dry eye: a randomised controlled study protocol.
Chen, Jiayan; Qin, Guanghao; Yu, Sile; Moore, Jonathan; Xu, Ling; He, Wei; Pazo, Emmanuel Eric; He, Xingru.
Afiliação
  • Chen J; He Eye Specialist Hospital, Shenyang, Liaoning, China.
  • Qin G; He Eye Specialist Hospital, Shenyang, Liaoning, China.
  • Yu S; He Eye Specialist Hospital, Shenyang, Liaoning, China.
  • Moore J; He University, Shenyang, Liaoning, China.
  • Xu L; Cathedral Eye Clinic, Belfast, UK.
  • He W; He Eye Specialist Hospital, Shenyang, Liaoning, China.
  • Pazo EE; He Eye Specialist Hospital, Shenyang, Liaoning, China.
  • He X; He Eye Specialist Hospital, Shenyang, Liaoning, China ericpazo@outlook.com hexingru@huh.edu.cn.
BMJ Open ; 14(2): e078727, 2024 Feb 26.
Article em En | MEDLINE | ID: mdl-38413161
ABSTRACT

INTRODUCTION:

The lipid layer of the tear film is critical to maintaining the integrity of the tear film and absence in the tear film lipid layer (TFLL) is one of the main causes of evaporative dry eye (EDE) in dry eye disease patients, resulting in excessive evaporation (so-called hyperevaporative dry eye). This study protocol will be designed to assess and compare the effects of intense pulsed light (IPL), heated eye mask (HEM), vectored thermal pulsation system (VTPS) and eyelid massage device (EMD) for improving signs and symptoms of EDE. METHODS AND

ANALYSIS:

Patients with EDE will be randomly divided into IPL, HEM, VTPS and EMD groups and will be followed up for 6 weeks. The primary outcome measure will be non-invasive tear breakup time (NITBUT). The secondary outcome measures will include, TFLL score, meibomian gland quality and expressibility change from baseline conjunctivocorneal staining with fluorescein and lissamine, tear meniscus height, conjunctival hyperaemia (redness score) and ocular surface disease index questionnaire. Additionally, adverse events will be monitored and documented. ETHICS AND DISSEMINATION Ethics approval number IRB(2023)K019.01. The findings will be shared regardless of the effect's direction. TRIAL REGISTRATION NUMBER NCT05923528.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Síndromes do Olho Seco / Glândulas Tarsais Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Síndromes do Olho Seco / Glândulas Tarsais Idioma: En Ano de publicação: 2024 Tipo de documento: Article